Key Highlights

  • Revenue was USD 21.61 million against USD 21.19 million estimated; non-GAAP Earnings were USD 0.20 per share against 0.16.
  • Revenue fell 17% from USD 26.1 million; adjusted EBITDA was USD 6.3 million and GAAP Net Income USD 1.2 million.
  • Revenue guidance moved to USD 87 to 93 million, and EBITDA guidance stayed at USD 21 to 25 million.
  • Contracted 2026 Revenue tracks about 20% below the prior year, and gross Margin is in the low 70% range.

OptimizeRx Corporation (NASDAQ:OPRX) reported third quarter 2026 revenue of USD 21.61 million against an estimate of USD 21.19 million, a beat of about 2.0%. Non-GAAP earnings were USD 0.20 per diluted share against an estimate of USD 0.16, which was also the prior year's non-GAAP result. The company reported after the market close on November 11, 2026, and held its Earnings Call that day.

Management said revenue of USD 21.6 million was a decrease of 17% from USD 26.1 million in the third quarter of 2025, and that revenue and adjusted EBITDA of USD 6.3 million both exceeded consensus expectations.

Earnings Detail

GAAP net income was USD 1.2 million, or USD 0.06 per basic and diluted share, against USD 0.8 million, or USD 0.04, a year earlier. Non-GAAP net income was USD 3.8 million, or USD 0.20 per diluted share, against USD 3.1 million, or USD 0.16. The source table figure of USD 0.20 is the non-GAAP measure.

Management said expenses reflected lower cost of revenue and compensation related costs, despite USD 0.7 million of severance costs from a previously announced reduction in force. It said margin optimization initiatives over the last 18 months continue to Yield benefits, with gross margin in the low 70% range for full year 2026.

Guidance and Customer Commentary

Management said contracted revenue for 2026 continues to track approximately 20% below the comparable prior year. It updated full year 2026 revenue guidance to a range of USD 87 million to USD 93 million, while maintaining adjusted EBITDA guidance of USD 21 million to USD 25 million.

Management said a customer that represented a meaningful portion of 2025 revenue but generated none in the first three quarters of 2026 returned in the third quarter. It said spending has not yet returned to historical levels, which it views as an encouraging sign of renewed engagement and a contribution to growth in 2027.

Management also described expanded opportunities within key accounts, signs of pent up Demand as customers ramp up the 2027 request for proposal season, and growing opportunities tied to its programmatic distribution capabilities.

Leadership and Items to Follow

Management said a new chief Marketing officer with more than two decades of pharmaceutical marketing experience joined during the quarter, and that a new chief financial officer and chief accounting officer assume their roles effective January 1, 2027.

The items to follow are contracted revenue for 2027, customer spending levels, gross margin and the effect of the Leadership transition. Non-GAAP figures exclude items the company defines in its release. The company's legal proceedings and related disclosures are flagged for human legal review.